CARDIOPROTECTIVE POSSIBILITIES PRO-HYPOXIC PRECONDITIONING

Cover Page

Cite item

Full Text

Abstract

Ischemia/hypoxia is an imbalance between the delivery of oxygenated blood to the myocardium and its oxygen demand. The metabolism of cardiomyocytes plays a definite role in the pathogenesis of heart failure, determines the development of such direction in the treatment of this syndrome as cardiocytoprotection. Review is dedicated to the effects of short-term and long-term hypoxic influence on locomotor cells in vivo and vitro. Historical background of the study of hypoxia and hypoxic conditions and pathophysiological mechanisms of hypoxia effects on the myocardium are briefly discussed. Examples of activation of the genetic apparatus in response to ischemia, some physiological changes at the tissue and cellular levels are given. The issues of possible defense mechanisms and activation of adaptive processes in response to subthreshold and threshold hypoxic influence are considered. The authors conclude about the prospects of the search techniques, which have a mild pro-hypoxic effect in the treatment of coronary heart disease.

About the authors

A. V. Lyubimov

S.M. Kirov Military Medical Academy

Author for correspondence.
Email: lyubimov_av@mail.ru
Russian Federation

D. V. Cherkashin

S.M. Kirov Military Medical Academy

Email: dm-cherk@yandex.ru
Russian Federation

References

  1. Житникова Л. М. Метаболическая терапия, или кардиоцитопротекция - как необходимый компонент комбинированной терапии сердечно-сосудистых заболеваний // РМЖ. - 2012. - № 4. - С. 137-143.
  2. Амосова Е. Н. Метаболическая терапия повреждений миокарда, обусловленных ишемией. Новый подход к лечению ишемической болезни сердца и сердечной недостаточности // Укр. кард. журн. - 2000. - № 4. - С. 86-88.
  3. Оковитый С. В. Клиническая фармакология антигипоксантов (часть I) // ФАРМиндекс-Практик. - 2004. - Вып. 6. - С. 30-39.
  4. Ратманова А. Прекондиционирование миокарда: естественные механизмы кардиопротекции в норме и патологии // Medicine Review. - 2008. - № 3 (03). - P. 27-37.
  5. Rezkalla S. H., Kloner R. A. Preconditioning in humans // Heart Fail Rev. - 2007. - Vol. 12. - P. 206.
  6. Зарубина И.В. Современные представления о патогенезе гипоксии и ее фармакологической коррекции // Обзоры по клин. фармакол. и лек. терапии. - 2011. - Т. 9, № 3. - С. 31-48.
  7. Зарубина И.В., Шабанов П. Д. Молекулярная фармакология антигипоксантов. - СПб.: Н-Л, 2004. - 368 с.
  8. Зарубина И.В., Шабанов П. Д. От идеи С. П. Боткина о «предвоздействии» до феномена прекондиционирования. Перспективы применения феноменов ишемического и фармакологического прекондиционирования // Обз. по клин. фармакол. и лек. терапии. - 2016. - Т. 14, № 1. - С. 4-28.
  9. Гипоксия: механизмы, адаптация, коррекция: мат-лы 5 Рос. конф. с междунар. участием. - М., 2008. - 128 с.
  10. Kumar V. et al. Cellular responses to stress and toxic insults: adaptation, injury, and death // Robbins and Cotran Pathologic Basis of Disease. - Philadelphia: Saunders, 1999. - P. 3-42.
  11. Rusko H. K., Leppavuori A., Makela P. Living high-training low: a new approach to altitude training at sea level in athletes [abstract] // Med. Sci. Sports Exerc. - 1995. - Vol. 27 (Suppl. 5). - P. 6.
  12. Rusko H. K. et al. Effect of living in hypoxia and training in normoxia on sea level VO2max and red cell mass // Med. Sci. Sports Exerc. - 1999. - Vol. 31. - P. 86.
  13. Stray-Gundersen J., Chapman R. F., Levine B. D. «Living high = training low» altitude training improves sea level performance in male and female elite runners // J. Appl. Physiol. - 2001. - Vol. 91. - P. 1113-1120.
  14. Millet G. P., Roels B., Schmitt L. et al. Combining hypoxicmethods for peak performance // Sports Med. - 2010. - Vol. 40. - P. 1-25.
  15. Gore C. J., Clark S. A., Saunders P. U. Nonhematological mechanisms of improved sea-level performance after hypoxic exposure // Med. Sci. Sports Exerc. - 2007. - Vol. 39, № 9. - P. 1600-1609.
  16. Gore C. J. et al. Live high: train low increases muscle buffer capacity and submaximal cycling efficiency // Acta Physiol. Scand. - 2001. - Vol. 173, № 3. - P. 275-286.
  17. Saunders P. U., Telford R. D., Pyne D. B. et al. Improved running economy in elite runners after 20 days of simulated moderate-altitude exposure // J. Appl. Physiol. - 2004. - Vol. 96. - P. 931-937.
  18. Schmitt L. et al. Influence of «living high-training low» on aerobic performance and economy of work in elite athletes // Eur. J. Appl. Physiol. - 2006. - Vol. 97. - P. 627-636.
  19. Радченко А.С. Применение естественной и искусственной гипоксии в спортивной тренировке // Обз. по клин. фармакол. и лек. терапии. - 2016. - Т. 11, № 1. - С. 26-32.
  20. Gros G., Wittenberg B. A., Jue T Myoglobin’s old and new clothes: from molecular structure to function in living cells // J. Exp. Biol. - 2010. - Vol. 213. - P. 2713-2725.
  21. Kanatous S. B., Mammen P. P. A. Regulation of myoglobin expression // J. Exper. Biol. - 2010. - Vol. 213. - P. 2741-2747.
  22. Kanatous S. B. et al. Hypoxia reprograms calcium signaling and regulates myoglobin expression // Am. J. Physiol. Cell Physiol. - 2009. - Vol. 296. - P. C393-C402.
  23. Wilber R. L. Current trends in altitude training // Sports Med. - 2001. - Vol. 31. - P. 249-265.
  24. Wittenberg B. A. Both hypoxia and work are required to enhance expression of myoglobin in skeletal muscle. Focus on «Hypoxia reprograms calcium signaling and regulates myoglobin expression» // Am. J. Physiol. Cell Physiol. - 2009. - Vol. 296. - P. 390-392.
  25. Lin P. C., Kreutzer U., Thomas J. Myoglobin translational diffusion in rat myocardium and its Implication on intracellular oxygen transport // J. Physiol. - 2007. - Vol. 578. - P. 595-603.
  26. Bailey D. M., Davies B. Physiological implications of altitude training for endurance performance at sea level: a review // Br. J. Sports Med. - 1997. - Vol. 31. - P. 183-190.
  27. Gore C. J. et al. Increased serum erythropoietin but not red cell production after 4 wk of intermittent hypobaric hypoxia (4000-5500 m) // J. Appl. Physiol. - 2006. - Vol. 101. - P. 1386-1393.
  28. Levine B. D. Intermittent hypoxic training: fact and fancy // High Alt. Med. Biol. - 2002. - Vol. 3. P. 177-193.
  29. Levine B. D., Stray-Gundersen J. «Living high-training low»: effect of moderate-altitude acclimatization with low-al-titude training on performance // J. Appl. Physiol. - 1997. - Vol. 83. - P. 102-112.
  30. Rusko H. K., Tikkanen H., Peltonen J. E. Altitude and endurance training // J. Sports Sci. - 2004. - Vol. 22. - P. 928-944.
  31. Wilber R. L. Application of altitude/hypoxic training by elite athletes // Med. Sci. Sports Exerc. - 2007. - Vol. 39. - P. 1610-1624
  32. Wilber R. L., Stray-Gundersen J., Levine B. D. Effect of hypoxic «dose» on hysiological response and sea-level performance // Med. Sci. Sports Exerc. - 2007. - Vol. 39, № 9. - P. 1590-1599.
  33. Радченко А.С. Окись азота и гипоксия при адаптации к мышечной работе (краткий обзор) // Обз. по клин. фармакол. и лек. терапии. - 2016. - Т. 14, № 1. - С. 78-88.
  34. Cosby K. et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation // Nat. Med. - 2003. - Vol. 9. - P. 1498-1505.
  35. Guo S. et al. Vascular endothelial growth factor receptor-2 in breast cancer // Biochim. Biophys. Acta. - 2010. - № 1806 (1). - P. 108-121.
  36. Hickey P. R., Hansen D. D. High dose fentanyl reduces intraoperative ventricular fibrillation in neonates with hypoplastic left heart syndrome // J. Clin. Anesth. - 1991. - Vol. 3. - Р. 295-300.
  37. Jensen F B. The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow // J. Exp. Biol. - 2009. - Vol. 212. - P. 3387-3393.
  38. Jia L., Bonaventura C., Bonaventura J., Stamler J. S. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control // Nature. - 1996. - Vol. 380. - P. 221-226.
  39. Kirino T. Ichemic tolerance // J. Cereb. Blood flow metab. - 2002. - Vol. 22, № 11. - P. 1283-1296.
  40. Ellsworth M. L. et al. The erythrocyte as a regulator of vascular tone // Amer. J. Physiol. - 1995. - Vol. 269. - P. 2155-2161.
  41. Gladwin M. T. et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cyto-protection, and vasodilation // Amer. J. Physiol. Heart Circ Physiol. - 2006. - Vol. 291, № 5. - Р. 2026-2035.
  42. Gonzalez-Alonso J. ATP as a mediator of erythrocyte-dependent regulation of skeletal muscle blood flow and oxygen delivery in humans // J. Physiol. - 2012. - Vol. 590. - P. 5001-5013.
  43. Gonzalez-Alonso J. et al. Erythrocytes and the regulation of human skeletal muscle blood flow and oxygen delivery: role of erythrocyte count and oxygenation state of haemoglobin // J. Physiol. - 2006. - Vol. 572. - P. 295-305.
  44. Gonzalez-Alonso J., Olsen D. B., Saltin B. Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery: role of circulating ATP // Circ. Res. - 2002. - Vol. 91. - P. 1046-1055.
  45. Yellon D. M., Alkhulaifi A. M., Pugsley W. B. Preconditioning the human myocardium // Lancet. - 1993. - Vol. 342. - P. 276-277.
  46. Duncker D. J., Bache R. J. Regulation of Coronary Blood Flow During Exercise // Physiol. Rev. - 2008. - Vol. 88. - P. 1009-1086.
  47. Yue X., Lin X., Yang T., Yang X. et al. Rnd3/RhoE Modulates Hypoxia-Inducible Factor 1 /Vascular Endothelial Growth Factor Signaling by Stabilizing Hypoxia-Inducible Factor 1 and Regulates Responsive Cardiac Angiogenesis // Hypertension. - 2016. - Vol. 67. - P. 597-605.
  48. Marzilli M., Orsini E., Marraccini P., Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction // Circulation. - 2000. - Vol. 101, № 18. - P. 2154-2159.
  49. Madonna R. et al. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Itali1an Society of Cardiology // Int. J. Cardiol. - 2015. - Vol. 191. - P. 203-210.
  50. Любимов А.В., Шабанов П. Д. Ишемия, реперфузия и прекондиционирование: традиционные и новые подходы в лечении инфаркта миокарда // Обз. по клин. фармакол. и лек. терапии. - 2016. - Т. 14, № 3. - С. 3-11.
  51. Ross A. M. et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) // J. Am. Coll. Cardiol. - 2005. - Vol. 45, № 11. - P. 1775-1780.
  52. Маслов Л. Н. Новые подходы к профилактике и терапии ишемических и реперфузионных повреждений сердца при остром инфаркте миокарда // Сиб. мед. журн. - 2010. - Т. 25, № 2. - Вып. 1. - С. 17-24.
  53. Пархоменко А. Н. Жизнеспособный миокард и кардиоцитопротекция. Возможности метаболической терапии при острой и хронической формах ишемической болезни сердца // Укр. мед. час. - 2001. - № 3 (23). - С. 5-11.
  54. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis // Cell. - 2011. - № 146 (6). - P. 873-887.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies